Tenax Therapeutics, Inc. (TENX): Price and Financial Metrics
TENX Price/Volume Stats
| Current price | $0.34 | 52-week high | $13.34 |
| Prev. close | $0.35 | 52-week low | $0.28 |
| Day low | $0.34 | Volume | 315,215 |
| Day high | $0.36 | Avg. volume | 2,761,332 |
| 50-day MA | $0.35 | Dividend yield | N/A |
| 200-day MA | $1.94 | Market Cap | 7.49M |
TENX Stock Price Chart Interactive Chart >
Tenax Therapeutics, Inc. (TENX) Company Bio
Tenax Therapeutics, Inc., a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. The company was founded in 1967 and is based in Morrisville, North Carolina.
Latest TENX News From Around the Web
Below are the latest news stories about TENAX THERAPEUTICS INC that investors may wish to consider to help them evaluate TENX as an investment opportunity.
Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)Once granted, this patent will provide intellectual property protection until December 2040, and may qualify for additional U.S. patent term extension beyond 2040 There are currently no FDA approved treatments for PH-HFpEF, a condition affecting more than 1,600,000 North Americans, with estimates indicating a prevalence of more than 2,000,000 patients by 2030Once granted, this patent will significantly broaden Tenax’s U.S. intellectual property (IP) protection for a market with the potential to |
TENX: Prioritizing LevosimendanBy John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT First Quarter Financial and Operational Review Tenax Therapeutics, Inc. (NASDAQ:TENX) reported 1Q:23 results on May 15, 2023 via its filing of Form 10-Q with the SEC. Despite the slow pace of advancement, we are impressed with the clinical data for both of Tenax’ PAH assets: levosimendan and imatinib. We see tremendous |
10 Stocks Targeted By Short Sellers RecentlyIn this piece, we will take a look at ten stocks targeted by short sellers recently. For more stocks, head on over to 5 Stocks Targeted By Short Sellers Recently. A curious outcome of the turmoil ushered in by the coronavirus pandemic was the historic tussle between retail and institutional investors. The pandemic made major […] |
Tenax Therapeutics Prioritizes Development Of TNX-103 For Heart FailureTenax Therapeutics Inc (NASDAQ: TENX) has decided to prioritize the Phase 3 testing of TNX-103 (oral levosimendan), with plans to commence a levosimendan Phase 3 study in 2023. The move is based on a strategic review process that began in September 2022. The decision to prioritize the clinical development of TNX-103 ahead of imatinib is based on several factors, including a growing intellectual property estate that encompasses the use of levosimendan to treat PH-HFpEF in the U.S. In March, the U |
Tenax Therapeutics Provides 2023 Business UpdateCompany to prioritize the clinical development of TNX-103 (oral levosimendan) for the treatment of pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF)PH-HFpEF affects more than 1,600,000 North Americans, with estimates indicating a prevalence of more than 2,000,000 patients by 2030Strategic decision based upon this significant unmet medical need, no FDA-approved therapies, and an expanding patent estate covering the use of levosimendan to treat PH-HFpEF which cou |
TENX Price Returns
| 1-mo | 4.42% |
| 3-mo | -40.33% |
| 6-mo | -87.31% |
| 1-year | -97.28% |
| 3-year | -98.83% |
| 5-year | -99.73% |
| YTD | -84.74% |
| 2022 | -89.29% |
| 2021 | -44.09% |
| 2020 | 31.91% |
| 2019 | 16.53% |
| 2018 | -87.65% |
Loading social stream, please wait...